Industrial component provider Timken (NYSE:TKR) will be reporting earnings tomorrow before market open. Here’s what you need ...

SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” first quarter ...

If daily knee pain is forcing you to rely on pain creams and pills, it might be time to consider total knee replacement (TKR) ...

Timken (TKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Investors looking for ...

The Timken Company has underperformed this year, with a YTD decline of 14%, worse than its mid-cap peers and other industrial ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Timken (TKR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is ...

Fintel reports that on April 21, 2025, DA Davidson downgraded their outlook for Timken (BMV:TKR) from Buy to Neutral. There are 810 funds or institutions reporting positions in Timken. This is an ...

BofA analyst Michael Feniger lowered the firm’s price target on Timken (TKR) to $68.50 from $85 and keeps a Neutral rating on the shares. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Total knee replacement (TKR) is one of the most common and successful orthopedic surgeries in the United States, with over 800,000 procedures performed annually (American Academy of Orthopaedic ...

The Timken Company designs, manufactures, and sells engineered bearings and industrial motion products, and related services in the United States and internationally. The company operates in two ...